以下文章来源于凤凰WEEKLY ，作者面二 凤凰WEEKLY . 有温度、有情感、有趣味 中国三甲医院，批量征服"外国中产"。 文 ｜ 面二 编辑 ｜ 章鱼 来源｜ 凤凰网WEEKLY（ID：phoenixweekly） 封面来源 ｜ IC Photo 来中国旅行，过去一年的外网 流量密码。 外网的" 中国旅游三件套"，甚至经历过两次迭代。 最开始，外网博主们来中国的必打卡项目还是：线上支付、高铁速度、酒店机器人。 这半年， 老外的 中国旅游新三件套 变成了：牙医、眼科、中医理疗。 TikTok的"Medical Tourism（医疗旅游）"的标签下，大批外国人摩拳擦掌准备到中国看病。 而他们的必打卡目的地，也新增了一个 三甲医院。 2024年，深圳为境外人士提供诊疗 服务77万人次，其中包括港澳人士64万人次，其余的则来自美国、加拿大、日本等国家。 上海13家指定医院接诊外籍患者近27万， 同比增长15%。 据国家卫生健康委员会2025年度涉外医疗服务报告显示：国内重点涉外医院全年接诊国际患者达128万人次，较三年前增长73.6%。 来中国边旅游边看病，正在成为一种风靡外网的新潮流。 新一批来中国旅游的外国 ...

转自：贵州日报 贵州日报天眼新闻记者 高琴 周旺泽 "全省人均预期寿命从2020年的75.2岁提升至2025年的76.8岁左右，居民健康素养水平实现'十连升'，妇 幼主要健康指标连续5年优于全国平均水平。"1月29日，省卫生健康委员会党组书记谭诤在"两会会客 厅"用一组扎实数据展现了"十四五"时期我省卫生健康事业的高质量发展图景。 面对新一年全面提升医疗服务能力的部署，谭诤表示，2026年将把省两会部署的各项任务和民生实事作 为重中之重，认真做到"七个更好统筹"，包括：更好统筹谋篇布局和重点突破，更好统筹内涵提升和体 系建设，更好统筹强基固本和守正创新，更好统筹公平可及和系统连续，更好统筹政策支持和人口发 展，更好统筹人才支撑和项目建设，更好统筹发展和安全，推动卫生健康事业和人口高质量发展。 "如今，大多数居民在15分钟内能够到达最近的医疗服务点，群众在家门口就能享受到更优质、更便捷 的医疗卫生服务。"谭诤介绍，贵州着力健全完善五级医疗卫生服务体系，推动优质医疗资源下沉。目 前，5个国家区域医疗中心和6个省级区域医疗中心建设项目已全部开诊运营，城市医疗集团和县域医共 体实现县级全覆盖，创新建设县域医疗次中心2 ...

智通财经APP获悉，瑞银发布研报称，现予泰格医药(03347)目标价57.1港元及"买入"评级。泰格医药发 布业绩预告，料2025年度营业收入同比增长1%至16%，意味第四季收入同比增长6.4%至72.9%，中位数 升39.6%高过该行及市场预期。不过，归属股东净利润预计为8.3亿至12.3亿元人民币，同比升105%至 204%，则低过该行及市场预期。 公司指，2025年新签订单的价格趋于稳定，但仍同比下滑，对利润率构成压力，公司同时强调临床研发 需求正复苏。瑞银关注泰格医药2026年新签订单的价格复苏讯号，以及管理层对2026年收入及利润的指 引。 ...

Core Viewpoint - The city has launched a pilot program for internet-based first consultations in pediatric care, aiming to enhance accessibility and efficiency of medical services for patients, particularly those from outside the city [1][3]. Group 1: Pilot Program Details - The pilot program is initiated at Beijing Children's Hospital and Capital Institute of Pediatrics, focusing on three pediatric subspecialties: growth and development, nutrition, and skin diseases [1]. - The program allows for online pre-consultation, online diagnosis, and medication delivery, marking a shift from offline to online first consultations for suitable conditions [1][3]. Group 2: Physician Qualifications and Management - The city health commission has set clear qualifications for first consultation physicians, requiring at least three years of independent clinical experience and a minimum of one year in internet-based follow-up consultations [2]. - There will be dynamic management of the physicians to ensure high-quality service delivery, along with a comprehensive oversight mechanism to monitor compliance with regulations [2]. Group 3: Patient Benefits and Accessibility - The pilot aims to leverage the concentration of quality medical resources in the city to provide efficient online services for a high volume of out-of-town patients, reducing their travel and associated costs [3]. - Patients can book online consultations through designated platforms starting from January 31, with the earliest appointments available on February 1 [2].

公司公告汇总 西安国际医学投资股份有限公司预计2025年度归属于上市公司股东的净利润亏损29,500万元至31,500万 元，较上年同期亏损25,412.85万元同比扩大。扣除非经常性损益后的净利润预计亏损32,000万元至 35,000万元。营业收入预计为406,000万元至408,000万元，较上年同期481,546.68万元下降。公司称受市 场波动、DRG支付政策改革等因素影响，营业收入同比下降，虽实施降本增效措施使第四季度亏损收 窄，但收入规模尚未覆盖运营成本和期间费用。本次业绩预告未经注册会计师审计。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 业绩披露要点：国际医学预计2025年归属净利润亏损2.95亿元至3.15亿元。 公司公告汇总：国际医学2025年度营收预计为40.6亿元至40.8亿元，同比下滑。 截至2026年1月30日收盘，国际医学（000516）报收于4.89元，较上周的5.21元下跌6.14%。本周，国际 医学1月26日盘中最高价报5.26元。1月30日盘中最低价报4.84元。国际医学当前最新总市值10 ...

Group 1 - The market regulatory authority has intensified supervision in key livelihood areas such as healthcare, pharmaceuticals, medical devices, food, and children's myopia prevention, announcing ten typical cases of illegal advertising [1][2] - Guangzhou Jianmei Health Technology Co., Ltd. was fined 600,000 yuan for false advertising claims regarding children's eye health products, including "children's lutein" and "eye nose probiotics" [1] - Nala Zun Camel (Guangzhou) Dairy Co., Ltd. was fined 450,000 yuan for misleading claims in its advertising of "camel milk powder" related to disease prevention and treatment [1] - Inner Mongolia Caozhilou Biotechnology Co., Ltd. was fined 200,000 yuan for advertising "organic perilla seed oil" with claims of cancer prevention [1] Group 2 - Chongqing Linhui Tai Business Information Consulting Co., Ltd. was fined 160,000 yuan for advertising "986 germ life enzyme" and other products with false claims about treating serious diseases [2] - Hangzhou Qingbi Brand Management Co., Ltd. was fined 190,000 yuan for misleading claims in advertisements for various health products, including "myopia astigmatism lutein eye patches" [2] - Songyuan Anorectal Hospital was fined 100,000 yuan for false claims regarding its affiliation with reputable medical institutions, affecting public trust and safety [2] Group 3 - Yunnan Yuyao Biopharmaceutical Co., Ltd. was fined 100,000 yuan for violating advertising regulations by promoting a prescription drug, "Sanqi Fatty Liver Pill," inappropriately [3]

Core Viewpoint - The article highlights the increasing regulatory scrutiny on misleading advertisements in key consumer sectors such as healthcare, pharmaceuticals, medical devices, and food, particularly focusing on children's eye care and cancer treatment products. Group 1: Misleading Advertisements - Guangzhou Jianmei Health Technology Co., Ltd. was fined 600,000 yuan for advertising products like "children's lutein" and "eye protection lamp" with false claims about disease prevention and treatment [1] - Nala Zun Tuo (Guangzhou) Dairy Co., Ltd. faced a fine of 450,000 yuan for misleading claims in its "camel milk powder" advertisements regarding health benefits [1] - Jingdezhen Yuxin Yicai Ceramics Co., Ltd. was fined 287,200 yuan for misleading consumers by falsely advertising its ceramic tableware as "Jingdezhen porcelain" [1] Group 2: Health Claims in Food Products - Inner Mongolia Caozhilou Biotechnology Co., Ltd. was fined 200,000 yuan for advertising "organic perilla seed oil" with claims of cancer prevention and treatment [2] - Chongqing Linhui Tai Business Information Consulting Co., Ltd. was fined 160,000 yuan for promoting products like "986 germ life enzyme" with false health claims and misleading language [2] - Hangzhou Qingbi Brand Management Co., Ltd. was fined 190,000 yuan for advertising "nearsightedness and astigmatism eye patches" with exaggerated claims about restoring vision [2] Group 3: Real Estate and Medical Device Misleading Claims - Anhui Kangqiao Real Estate Co., Ltd. was fined 150,000 yuan for misleading advertising regarding unplanned facilities in its real estate promotions [3] - Shandong Chengshi Chengshi E-commerce Co., Ltd. was fined 105,000 yuan for advertising unapproved medical devices and health claims related to digestive issues [3] - Yunnan Yuyao Biopharmaceutical Co., Ltd. was fined 100,000 yuan for violating advertising regulations for prescription drugs [3] Group 4: Regulatory Actions - In 2025, national market regulatory authorities handled 44,521 cases of advertising violations, imposing fines totaling 252 million yuan, reinforcing consumer rights protection [4]

百余家医药企业发布业绩预告 19家年内实现业绩翻身 1月30日，新京报贝壳财经记者根据Wind数据整理发现，474家医药企业中，255家已发布2025年业绩预告。81家企业释放出积极信号，其中，50家企业出现 业绩预增，6家业绩略增。 | 业绩预告类型 | 数量 | | --- | --- | | 不确定 | 1 | | 略減 | 3 | | 略增 | 6 | | 扭亏 | 24 | | 首亏 | 38 | | 续亏 | 90 | | 续盈 | 1 | | 预减 | 42 | | 预增 | 50 | | 总数 | 255 | 近日，A股医药板块上市公司开始密集披露2025年度业绩预告。据新京报贝壳财经统计，截至1月30日，已有255家相关企业公布了业绩预告数据。 其中超三成企业释放积极信号——50家业绩预增、24家实现扭亏，打赢"翻身仗"，化学制药、医疗器械、医疗服务等领域企业表现突出。 值得注意的是，海外市场成为多家企业增长的共同引擎。以理邦仪器为例，公司在业绩预告中强调"国际市场保持两位数增长"。与此同时，部分企业通过降 本增效、产品结构调整成功实现业绩逆转。 行业内部亦呈现结构性分化，从2025年业绩表 ...

（来源：医学界） 转自：医学界 今日（1月31日），国家卫健委网站发布《关于同意北京市规范开展互联网诊疗首诊试点工作的函》，同意北京市卫健委依托首都医科大学附 属北京儿童医院、首都医科大学附属首都儿童医学中心两家医院，开展儿童生长发育专业、儿童营养专业、儿童皮肤疾病专业互联网诊疗首诊 试点，试点时间为一年（2026年1月至12月）。 根据公告，国家卫健委对试点工作提出6项要求，其中包括医师开展互联网诊疗应当依法取得相应执业资质，具有3年以上独立临床工作经验； 为儿童提供互联网首诊服务时，应当确定患儿有监护人陪伴。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 你委《关于申请开展互联网诊疗首诊试点工作的请示》收悉。为充分利用信息技术疏解北京非首都功能，满足外地患者就医需求，经研究，同 意你委依托首都医科大学附属北京儿童医院和首都医科大学附属首都儿童医学中心开展儿童生长发育专业、儿童营养专业、儿童皮肤疾病专业 互联网诊疗首诊试点。现提出以下工作要求： 一、要落实监管责任。充分发挥北京市互联网诊疗监管平台作用，加强信息化监管和穿透式监管，确保医疗机构的执业信息、人员资质、诊疗 数据和活动 ...

Core Viewpoint - The establishment of the Digestive Endoscopy Specialty Committee marks a significant step towards the standardization, collaboration, and high-quality development of digestive endoscopy diagnosis and treatment in the region, contributing to the broader goal of building a healthy China [1][2] Group 1: Establishment and Objectives - The Digestive Endoscopy Specialty Committee aims to implement health-first development strategies and create a balanced healthcare service system [1] - The committee's formation is a practical measure to enhance early diagnosis and treatment capabilities for digestive system diseases and strengthen public health safety [1] Group 2: Collaborative Development - The alliance and specialty committee will focus on the development philosophy of "complementary advantages, collaborative development, and mutual benefit," enhancing cooperation among member units in various areas such as medical technology, talent training, and academic exchange [1] - The initiative aims to improve the comprehensive prevention and treatment capabilities for digestive system diseases in Anhui Province, providing more convenient and professional medical services to the public [1] Group 3: Academic Contributions - The conference featured a forum where 13 experts shared the latest research on clinical diagnosis and treatment of colorectal cancer, EUS quality control, and challenges in the treatment of esophageal achalasia [2] - Nearly 280 representatives from over 180 medical institutions participated in the conference, indicating strong interest and collaboration in the field [2]